C18-Ceramide (d18:1/18:0)
Based on 1 Customer Validation
C18-Ceramide (d18:1/18:0) is a bioactive molecule with multiple functions in cells, not a traditional agonist or inhibitor targeting a single site. It can act on multiple cellular targets, such as proteins related to endoplasmic reticulum stress (e.g., ATF-4, XBP-1, CHOP), proteins in the PI3K/AKT signaling pathway, and SNARE complex proteins. It exerts activities like inducing cell death, promoting autophagy, and regulating exocytosis through mechanisms such as activating endoplasmic reticulum stress, inhibiting the PI3K/AKT signaling pathway, and affecting lipid raft - related functions. It can be used in research on the mechanism of neuronal injury in the field of neuroscience and in the treatment research of cancers such as glioma in the field of oncology.
For research use only. We do not sell to patients.
- Purity: 99.95%
- CAS No.: 2304-81-6
- Formula: C36H71NO3
- Molecular Weight:565.95
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
All Endogenous Metabolite Isoforms
More
Biological Activity
In the PC12 cell capacitance measurement experiment, C18-Ceramide (d18:1/18:0) (2 μM; transient) can significantly increase the cell membrane capacitance, indicating that it can promote exocytosis[1].
In the PC12 cell total internal reflection fluorescence microscopy (TIRFM) experiment, C18-Ceramide (d18:1/18:0) (2 μM) can rapidly reduce the number of NPY-EGFP-labeled subcellular membrane vesicles, which undergo endocytosis by fusing with the cell membrane[1].
In U251 and A172 glioma cells, C18-Ceramide (d18:1/18:0) (20 μM; 48 h) inhibits glioma cell viability and induces cell death[2].
C18-Ceramide (d18:1/18:0) (20 μM; 48 h) activates endoplasmic reticulum stress and increases the mRNA and protein levels of ATF-4, XBP-1 (s) and CHOP[2].
C18-Ceramide (d18:1/18:0) induced lethal autophagy, increased the punctate distribution and density of GFP-LC3, promoted the conversion of LC3B-I to LC3B-II and decreased the level of p62[2].
C18-Ceramide (d18:1/18:0) inhibited the PI3K/AKT pathway and decreased the expression levels of PI3K and p-AKT (S473)[2].
C18-Ceramide (d18:1/18:0) (20μM; co-treatment with VM-26 for 48h) increased the chemosensitivity of U251 and A172 cells to VM-26 (HY-13761), synergistically inhibited cell growth, and induced more apoptosis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:U251, A172 glioma cells
-
Concentration:20 μM
-
Incubation Time:48 h
-
Result:Inhibited ell viability and induced cell death.
-
Cell Line:U251, A172 glioma cells
-
Concentration:20 μM
-
Incubation Time:48 h
-
Result:Increased the mRNA and protein levels of ATF-4, XBP-1(s), and CHOP.
-
Cell Line:U251, A172 glioma cells
-
Concentration:20 μM
-
Incubation Time:48 h
-
Result:Inhibited the expression levels of PI3K and p-AKT(S473).
-
Cell Line:U251, A172 glioma cells
-
Concentration:20μM (C18-Ceramide), with 0.25 μM VM-26 for U251 cells, or 10 μM VM-26 for A172 cells
-
Incubation Time:48 h
-
Result:Combined with VM-26, inhibited cell growth synergistically, and induced more apoptosis.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2304-81-6
-
Appearance Solid
-
Molecular Weight 565.95
-
Formula C36H71NO3
-
Color White to off-white
-
SMILES
CCCCCCCCCCCCCCCCCC(N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC)=O
-
Synonyms
C18-Ceramide
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
Ethanol : 5 mg/mL (8.83 mM; Need ultrasonic)
DMF : 1 mg/mL (1.77 mM; Need ultrasonic)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tang N, et al. Differential effects of ceramide species on exocytosis in rat PC12 cells. Exp Brain Res. 2007 Nov;183(2):241-7. [Content Brief]
[2]. Wang Z, et al. Overexpression of ceramide synthase 1 increases C18-ceramide and leads to lethal autophagy in human glioma. Oncotarget. 2017 Oct 23;8(61):104022-104036. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMF / Ethanol | 1 mM | 1.7669 mL | 8.8347 mL | 17.6694 mL | 44.1735 mL |
| Ethanol | 5 mM | 0.3534 mL | 1.7669 mL | 3.5339 mL | 8.8347 mL |